Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Estradiol + sertraline is a combination of two active pharmaceutical ingredients: estradiol, a synthetic form of the endogenous estrogen hormone, and sertraline, a selective serotonin reuptake inhibitor (SSRI) antidepressant. Estradiol acts primarily as an agonist at estrogen receptors to regulate gene expression and modulate reproductive and other physiological functions. Sertraline inhibits the sodium-dependent serotonin transporter, increasing synaptic serotonin levels in the central nervous system to exert antidepressant effects. This combination does not have an established fixed-dose product or unique brand name; it refers to concurrent use of both drugs for their respective indications—typically menopausal symptoms (estradiol) and mood disorders such as depression or anxiety (sertraline). There is some evidence that SSRIs like sertraline may interact with estrogenic pathways at the cellular level, potentially resulting in weak estrogenic or antiestrogenic effects when combined with estradiol[5]. However, no clinically significant pharmacokinetic drug-drug interactions are reported between these agents[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol + sertraline.